Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Dexmedetomidine hydrochloride
61
CHF
CHF 61.00
In stock
CDX-D0792-M01010 mgCHF 61.00
CDX-D0792-M05050 mgCHF 244.00
| Product Details | |
|---|---|
| Synonyms | Dex; Precedex; (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride; 4-[(S)-α,2,3-Trimethylbenzyl]imidazole monohydrochloride |
| Product Type | Chemical |
| Properties | |
| Formula |
C13H16N2 · HCl |
| MW | 236.74 |
| CAS | 145108-58-3 |
| RTECS | NI5156750 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to beige powder. |
| Solubility | Soluble in water (10mg/ml), ethanol (25mg/ml) or DMSO (20mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | VPNGEIHDPSLNMU-MERQFXBCSA-N |
| Smiles | CC1=C(C)C([C@@H](C2=CN=C[NH2+]2)C)=CC=C1.[Cl-] |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Dexmedetomidine hydrochloride is the active isomer of medetomidine and is a highly potent and selective α2-adrenergic agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively) with analgesic and sedative properties. Dexmedetomidine hydrochloride is used clinically as an anesthetic agent to reduce anxiety and tension and promote relaxation and sedation without causing respiratory depression. It is active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects.
Product References
(1) R. Virtanen, et al.; Eur. J. Pharmacol. 150, 9 (1988) | (2) H. Scheinin, et al.; Prog. Neuropsychopharm. Biol. Psychiat. 13, 635 (1989) (Review) | (3) R. Gertler, et al.; Proc. (Bayl. Univ. Med. Cent.) 14, 13 (2001) | (4) S. Bajwa & A. Kulshrestha; Ann. Med. Health Sci. Res. 3, 475 (2013) | (5) Y. Cai, et al.; Mol. Med. Rep. 9, 1542 (2014) (Review) | (6) M. Maze; Anesthesiology 125, 590 (2016) (Review) | (7) C. Tang & Z. Xia; J. Pain Res. 10, 1899 (2017) (Review)